Methyleugenol (1) is a constituent of many foods, in particular of herbal spices, and is used as flavoring agent in foodstuffs and as fragrance in cosmetics. 1 has been found to be carcinogenic in rodents, its metabolite, 1´-hydroxymethyleugenol (2) acting as proximate DNA-binding carcinogen. We incubated 1 with liver microsomes of rat, bovine, and human origin. We found 2, 3´-hydroxymethylisoeugenol (3), and 6-hydroxymethyleugenol (4) as major metabolites, and 1´-oxomethyleugenol (5), 3´-oxomethylisoeugenol (6), eugenol (9), chavibetol (11), and (RS)-2´,3´-dihydroxy-2´,3´-dihydromethyleugenol (7) as minor metabolites. Methyleugenol-2´,3´-epoxide (8), probably the precursor of 7, could not be detected. Incubations with synthetic metabolites were applied in order to uncover metabolic pathways. Incubations with primary rat hepatocytes revealed mainly nonconjugated 2 and conjugated 4, and minor amounts of partly conjugated 7 and conjugated 9 + 11. The "reactive metabolites" 3, 5, 6, and 8 were not detectable, possibly due to rapid reaction with cellular macromolecules. The highest cytotoxicity (resazurin reduction assay and lactate dehydrogenase leakage assay) was observed for the main metabolite 2 and its secondary metabolite 5 with EC 50 values of 50 and 10 µM, respectively. Deoxyadenosine or deoxyguanosine adducts were formed by incubating 1 or metabolites with rat hepatocytes. The rank order of adduct formation was 2 > 1 > 3 > 6, whereas 4, 5, and 8 were inactive. In conclusion, we present a virtually complete pattern of microsomal (rat, bovine, and human) and hepatocellular (rat) metabolites of 1 suggesting the formation of several reactive metabolites possibly involved in carcinogenicity, organ toxicity, and immune reactions.
Methyleugenol (4-allyl-1,2-dimethoxybenzene; 1) is an alkenylbenzene naturally occurring in foods, particularly in many herbal spices such as basil, nutmeg, tarragon, star anise, and fennel. Moreover, 1 is used as a flavoring substance in various food products, cosmetics, soaps, etc. (SCF, 2001) . Although 1 has been classified as "generally recognized as safe" by the Flavor and Extract Manufacture Association in 1965, more recent data point to a genotoxic and carcinogenic potential of the substance.
Treatment of mice with 1 by ip injection resulted in increased formation of hepatoma . In a 2-year study in rats and mice, 1 was found to act as a multisite, multispecies carcinogen leading, e.g., to hepatic and neuroendocrine tumors, and tumors at other sites such as the forestomach, glandular stomach, and kidney (Johnson et al., 2000; NTP, 2000) . The carcinogenicity of 1 is supposed to result from its metabolic activation to the proximate carcinogen 1´-hydroxymethyleugenol (2) catalyzed by cytochrome(s) P450 (CYP) (Chan and Caldwell, 1992; Howes et al., 1990) . Via enzyme-catalyzed sulfation, the unstable sulfate ester of 2 is formed which, upon loss of the sulfate moiety, forms a highly reactive carbocation. The latter can react covalently with DNA causing mutations and tumors (Burkey et al., 2000) . This mechanism is supported by the finding that mice, treated with the structurally related safrole, estragole, or 1´-hydroxysafrole together with pentachlorophenol (PCP), a potent sulfotransferase (SULT) inhibitor, formed no or significantly less hepatoma at the same dosages compared with those without cotreatment with PCP (Boberg et al., 1983; Wiseman et al., 1987) . In rat liver microsomes, CYP2E1 was found to be the major CYP-enzyme catalyzing the 1´-hydroxylation of 1 (Gardner et al., 1997) . Moreover, treatment of rats with 1 caused an auto-induction of other 1´-hydroxylating enzymes such as CYP2B and 1A2. With human liver microsomes (HLMs), we found a marked variability in the rate of 1´-hydroxylation of 1 with the highest activities being similar to the activity found in control rat liver microsomes. Using HLMs from different donors, Jeurissen et al. (2006) found evidence for CYP1A2 being the most toxicological sciences 129(1), 21-34 (2012) doi:10.1093/toxsci/kfs181 Advance Access publication May 18, 2012 important enzyme converting 1 at physiologically relevant concentrations into 2. Other human enzymes contributing to this reaction, presumably mainly at higher substrate concentrations, are CYP2C9, 2C19, and 2D6. Similar pathways of activation have been reported for related alkenylbenzenes, such as safrole or estragole (Jeurissen et al., 2007) . Evidence has also been provided for the formation of 2´,3´-epoxides at the allylic side chain. In the case of safrole and estragole, the 2´,3´-epoxides have also been shown to form DNA adducts (Luo and Guenthner, 1996; Phillips et al., 1981) possibly contributing to a carcinogenic potential (Swanson et al., 1981) . In urine of rats treated with different allylbenzenes including 1 and in rat liver microsomes incubated with the same compounds, the corresponding 2´,3´-dihydrodiols have been detected (Delaforge et al., 1980) . Furthermore, the reactivity of metabolites of 1 with proteins may lead to hapten formation and subsequent sensitization. In fact, 1 is listed as a suspected allergen in the European Unions's Cosmetics Directive 76/776/EEC (EU, 2008) .
In rats in vivo (Ellis et al., 2006) and in human HepG2 cells (Zhou et al., 2007) , 1 formed DNA adducts detected by the 32 P-postlabeling method. However, the nature of these adducts was not investigated. In addition, 1 and several metabolites were found to induce DNA strand breaks in the comet assay (Ding et al., 2011; Groh et al., 2012) . Both enantiomers of 2 and the (E)-3´-hydroxymethylisoeugenol (3) were mutagenic and formed DNA adducts in a modified Ames test using Salmonella typhimurium strains expressing different SULTs (Herrmann et al., 2012) .
In this study, we investigate the entire phase I metabolism of 1 in liver microsomes of human, rat, and bovine origin with a special emphasis on potentially reactive metabolites distinct from the products of the well-described 1´-side-chain hydroxylation-sulfation pathway. Furthermore, we analyze the pattern of metabolites released from intact rat hepatocytes and identify DNA base adducts in the same cell type.
MATERIALS AND METHODS

Chemicals and materials. Acetone and dimethyl sulfoxide (DMSO)
were purchased from Merck (Darmstadt, Germany). β-glucuronidase/sulfatase (G7017), β-NADP, glucose-6-phosphate, glucose-6-phosphate dehydrogenase, eugenol (9), isoeugenol (10), and 1 were obtained from Sigma Aldrich/ Fluka (Taufenkirchen, Germany). Methanol was obtained in high-performance liquid chromatography (HPLC) gradient grade from J.T. Baker (Griesheim, Germany). Aroclor 1254 was originally purchased from Monsanto (St Louis, MO). 2, 3, 6-hydroxymethyleugenol (4), (E)-3´-oxomethylisoeugenol (6), (RS)-2´,3´-dihydroxy-2´,3´-dihydromethyleugenol (7), 6-hydroxymethylisoeugenol (12), (E)-3,4-dimethoxycinnamic acid (13), and 3,4-dimethoxypropylbenzene (14) were synthesized according to the procedures previously described by our group (Cartus et al., 2011) . 1´-oxomethyleugenol (5), (R/S)-methyleugenol-2´,3´-epoxide (8), chavibetol (11), and 3,4-dihydroxyallylbenzene (15) were synthesized using the methods described in the synthesis section. Analytical data (nuclear magnetic resonance- [NMR] , ultraviolet light/visible light-[UV/ Vis], and liquid chromatography-mass spectrometry [LC-MS] data) of all synthesized metabolites are summarized in the supplementary tables 1 and 2. All consumables were purchased from Greiner Bio-one (Frickenhausen, Germany).
Analytical methods.
1 H-NMR and 13 C-NMR spectra were recorded on a Bruker (Bruker BioSpin, Rheinstetten, Germany) DPX 400 or Avance 600 spectrometer in DMSO-d 6 ( 1 H-NMR: δ 2.49 ppm, 13 C-NMR: δ 39.5 ppm) or CDCl 3 ( 1 H-NMR: δ 7.26 ppm, 13 C-NMR: δ 77.0 ppm) at 298 K. Thin-layer chromatography was performed on silica gel 60 F-254 plates (Merck). IR spectra were recorded on a JASCO FT/IR-6100 spectrophotometer (Jasco, Gross-Umstadt, Germany). The LC-MS/MS system (for identification of phase I metabolites) consisted of a PerkinElmer (Waltham, MA) LC-system coupled to an API 2000 QTRAP instrument (AB SCIEX, Foster City, CA). The mass spectrometer was operated using an electrospray ionization source in the positive ion mode (ESI+) for all metabolites except metabolites 9 and 11, which had much higher signal intensities in the negative mode (ESI−). Acquisition and data processing were carried out with the Analyst software version 1.4.2 (Applied Biosystems). The instrumental settings used for full ion scans (m/z 50-300) were as follows: ion source temperature 400°C, declustering potential 20 V, focusing potential 200 V, entrance potential 5.0 V, curtain gas 20, ion source gas, 20, and turbo gas, 20, (the latter three are given in arbitrary units in the Analyst software). The conditions for fragmentation experiments were collision-associated dissociation gas pressure of 5 (arbitrary units), collision energy 15 eV, and a cell entrance potential 10.7 V.
Analytical HPLC was carried out using an Agilent 1100 HPLC system equipped with an autosampler (G1329A), a quadruple pumping system (G1311A), a diode array spectrophotometer (DAD G1315A), and a column heater (G1316A; Agilent, Waldkirch, Germany).
HPLC and LC-MS/MS separations were performed using a C18 column (5 µm, 4.0 × 125 mm; Highbar, LiChrosorb, Merck). The mobile phase system consisted of A (10 mM NH 4 OAc in water) and B (pure MeOH). Separation was achieved using a 30-min linear gradient to 70% B from initial conditions of 10% B, following a 5-min period with constant eluent composition of 70% B with a total analysis time of 38 min per sample at a flow rate of 1 ml/min. The column temperature was kept constantly at 35°C and detection wavelengths were 230, 261, and 280 nm. Injection volumes were 50 µL. Preparative HPLC was performed with an Agilent 1200 series system comprising two preparative pumps (G1361A), an automatic fraction collector (G1364B), and a multiwave detector (G1315A). Injection was achieved over a manual valve with sample loops of 2.0 mL (incubations) or 10.0 mL (synthesis) volume. As column, a RP18 (Reprosil 100, 5 µm, 250 × 20 mm; Dr. Maisch GmbH, AmmerbuchEntringen, Germany) was used.
5 mM glucose-6-phosphate, 3 mM magnesium chloride, and 50 mM phosphate buffer, pH 7.4. Incubations were carried out in various volumes (from 1 to 100 ml for preparative uses) and were gently shaken in an incubator (TH-30; Carl Roth, Karlsruhe, Germany) at 37°C. After preincubation with substrate for 5 min at 37°C, the NADPH-generating system was added and the mixture was incubated for up to 24 h. Control incubations were carried out with heatinactivated microsomes and with intact microsomes but without the NADPHregenerating system. The formation of NADPH was checked photometrically (Ying, 2008) . Incubations and time-course measurements were carried out in triplicate as independent experiments. The high concentration of DMSO (5%) was applied to improve solubility of the substrate, in particular of isolated metabolites. Although DMSO is known to act as a CYP inhibitor, concentrations of metabolites in control incubations of 1 using 0.5% DMSO with all types of microsomes were found not to be significantly different in the pattern of metabolites, but produced lower amounts of metabolites under otherwise identical conditions (data not shown).
Isolation, culture, and incubation of primary rat hepatocyte (pRH). Male Wistar rats weighting 150-250 g were purchased from Charles River. Rats were anesthetized with pentobarbital (100 mg/kg bw; ip) and livers were perfused in a two-step procedure according to Schrenk et al. (1992) . Cell vitality always exceeded 92%. Isolated hepatocytes were seeded on rat tail collagen-coated Petri dishes or multiwell plates in Dulbecco's modified Eagle's medium (low glucose, phenol red-free; PAA Laboratories, Cölbe, Germany) supplemented with 10% fetal calf serum and 1% antibiotics solution (streptomycin, penicillin; PAA Laboratories) and left for 4 h to attach. The medium was exchanged and cells were treated with 1 or the synthesized metabolites from 1000× stock solutions in DMSO. Medium and medium with DMSO were used as vehicle controls. The final DMSO concentration for all treatments was 0.1%. Cells were treated for 2 and 12 h (isolation of DNA) or 24 h (cytotoxicity).
Phase I and II metabolism of 1 in pRH. Metabolism studies with pRHs were carried out in 94-mm Petri dishes with 10 6 cells in 8.0 ml culture medium. The cells were pretreated with Aroclor 1254 (25 µM) for 48 h. The culture medium was exchanged, and 1 (200 µM) was added. Samples (2 × 200 µl of the incubation supernatant) were taken immediately after adding 1 (time 0 h) and then hourly over a time period of 5 h. One of each samples was (after work up, see Sample Preparation) directly applied to HPLC analysis, the other one was postincubated with glucuronidase/sulfatase. For this purpose, the samples were treated with 20 µl of acetate buffer (1.0 M; pH 5.5) and glucuronidase/sulfatase (400 units, 4 µl) and were incubated for 10 h in a shaking water bath at 37°C. Afterwards, samples were worked-up (see Sample Preparation) and used for HPLC analysis.
Isolation of DNA and determination of DNA adducts. DNA of pRH incubated with synthesized phase I metabolites of 1 for 2 or 12 h was extracted using a standard phenol/chloroform protocol as modified according to Wörner and Schrenk (1996) . DNA samples (12.5 µg) were spiked with internal standards (120 fmol
, digested to deoxyribonucleosides and analyzed by ultra performance liquid chromatography (UPLC)-MS/MS as described previously for other benzylic and allylic adducts (Monien et al., 2008 (Monien et al., , 2011 . Transitions of m/z 428 → 177 (loss of deoxyadenosine [dA] ) and 444 → 328 (loss of deoxyribose) were used as quantifiers for N 6 -MIE-dA and N 2 -MIE-dG, respectively. The corresponding transitions for the isotope-labeled internal standards were 433 → 177 and 449 → 333. Details of the UPLC-MS method are presented elsewhere (Herrmann et al., 2012) . The limits of quantification were 3 and 12 adducts per 10 8 nucleotides for N 6 -MIE-dA and N 2 -MIE-dG, respectively. The structure of the deoxyguanosine (dG) and dA adduct are presented in Supplementary figure 1. These adducts can be formed after incubation with 1, 2, 3, 5, 6, and methylisoeugenol. If 4 is activated via side-chain hydroxylation and sulfation, it could form adducts whose mass exceeded those of N 6 -MIE-dA and N 2 -MIE-dG by 16. Therefore, the corresponding DNA digests were additionally checked for adducts showing the transitions m/z 444 → 328 (dA adducts) and 460 → 344 (dG adducts), which reflect the loss of a sugar moiety, a characteristic transition for many other known deoxynucleoside adducts. Likewise, reaction of the oxirane ring of 8 might lead to adducts that contain an additional oxygen and two hydrogen atoms compared with N 6 -MIE-dA and N 2 -MIE-dG. Thus, the corresponding DNA digests were also checked for transitions of m/z 446 → 330 (dA adducts) and 462 → 346 (dG adducts).
Sample preparation. After incubation (microsomes or pRH), samples were diluted with equal volumes of an ice-cold solution of acetone (−20°C) containing 0.1 or 0.5 mM 14 as internal standard. Samples were cooled for 20 min on ice. pRH supernatants were additionally sonified (3-5 s). The mixtures were shaken vigorously, and the precipitated protein was removed by centrifugation (13,000 × g, 5 min). For time course measurements, the supernatants were used directly for HPLC analysis. For (semi-)preparative incubations, the supernatants were extracted five times with an equal volume of ethyl acetate. The solvent of the combined organic phases was removed, and the residue was dissolved in a defined volume of methanol.
Identification of metabolites. The identity of microsomal and hepatocyte metabolites was checked by comparison of their analytical data with the synthesized standards. All given metabolites match at least in their UV spectra and retention time with the standards. Spiking experiments were performed for all metabolites by adding approximately the same concentration of reference compound to the worked-up incubation solution, which did not produce any additional signals or shoulders (data not shown). Further confirmation of the metabolites' identities by LC-MS/MS was performed by detecting at least one prominent transition (at the corresponding retention time) determined with the analytical standards (Supplementary table 1 ). In addition, the identity of metabolites was verified by 1 H-NMR spectroscopy if the isolated amount from incubation solutions was sufficient.
Quantification of metabolites.
For quantification of the microsomal metabolites, the synthesized reference compounds were analyzed at concentrations of 1, 10, 50, 100, 500, and 1000 µM in methanol with the HPLC gradient described under the Analytical Methods section. Injection volumes were 50 µl each. Peak areas (area under the curve) detected at five different wavelengths (λ = 230, 261, 280, 310, and 340 nm) were plotted versus concentration. Metabolite concentrations were calculated from the slope of the linear regression (R 2 ≥ 0.99 for each compound) at the most sensitive wavelength. As internal standard, 14 was used. Its retention time was 31 min, a time when no metabolites were found to elute.
Cytotoxicity assays. The cytotoxicity of synthesized metabolites was determined using two methods, the resazurin assay and lactate dehydrogenase (LDH)-leakage assay (LLA) at concentrations ranging from 1.0 µM to 1.0-2.5 mM depending on solubility in DMSO.
The resazurin reduction assay (RRA) was performed by the method of O' Brien et al. (2000) using 24-well plates at a density of 2 × 10 5 pRHs per well in 1.0 ml culture medium. Viability was determined spectrophotometrically (excitation λ = 544; emission λ = 590 nm) (Fluoroskan Ascent FL; Thermo Fisher Scientific, Waltham, MA). Viability was calculated as percentage of the difference between reduction of resazurin in treated versus nontreated cells with 1.0% saponin as positive control.
The release of LDH from pRH was measured according to the method of Moran and Schnellmann (1996) using 60-mm Petri dishes (10 6 cells, 3 ml culture medium). After treatment for 24 h, LDH was determined spectrophotometrically (excitation λ = 360; emission λ = 460 nm) by an automatic plate reader (Fluoroskan Ascent FL; ThermoFisher Scientific) by measuring its activity in an aliquot of cell-free supernatant. The leakage into the media was calculated as percentage of total LDH activity determined after lysis of the cells by sonication together with the media supernatant. The solvent control was set to 100% viability, and the positive control (1.0% saponin) was set to 0% cell viability. The concentration-response data curves were fitted to a response using sigmoid regression. Results are expressed as 50% effective concentrations (EC 50 ).
Synthesis of metabolites. 5 was synthesized by the same method previously described for 6 (Cartus et al., 2011) 3083, 3005, 2962, 2937, 2840, 1662, 1594, 1583, 1553, 1540, 1515, 1464, 1452, 1421, 1403, 1341, 1267, 1208, 1168, 1151, 1132, 1098, 1023, 982, 882, 868, 814, 783, 767, 725, 665 , and 625 cm −1 ; t R (HPLC-UV) = 19.8 min (261 nm; 1.0 mM); UV/Vis (HPLC-DAD): λ max (absolute absorbance in mAU) = 230 (1800), 290 (1000), and 325 (1200) nm.
8 was synthesized by dissolving 1 (1.05 g, 5.86 mmol) in dichloromethane (25 mL) and stirred with a saturated solution of sodium bicarbonate (10 ml). At room temperature, meta-chloroperbenzoic acid (70%, 1.98 g, 8.03 mmol) dissolved in dichloromethane (15 ml) was added. The mixture was vigorously stirred for 2 h. The organic layer was separated, the aqueous phase was extracted three times with dichloromethane (30 ml), the combined organic phases were dried (MgSO 4 ), and the solvent was removed in vacuo. Purification by flash column chromatography yielded the epoxide as orange-colored oil (648 mg, 3.34 mmol, 57%). Analysis: R f = 0.29 (EtOAc/Hexan 1:3); 3583, 3414, 2997, 2936, 2836, 2281, 1719, 1650, 1606, 1591, 1518, 1465, 1420, 1335, 1262, 1237, 1157, 1141, 1028, 970, 833, 811, 765 , and 666 cm −1 . 11 was synthesized by two routes: A: unselective methylation of 15 and B: unselective O-demethylation of 1 (Hirao, 1936) . In both cases, the same products were observed. Route A: Under argon atmosphere, 15 (278 mg, 1.91 mmol) and potassium carbonate (760 mg, 5.0 mmol) were stirred in dry acetone (30 ml). Dimethyl sulfate (0.6 eq., 145 mg, 1.15 mmol, 109 µl) was added in one portion and the mixture was refluxed for 2 h. The reaction was controlled using HPLC. After addition of ethyl acetate (50 ml) and half-saturated ammonium chloride (50 ml), the organic layer was separated, washed with water and brine, and dried (MgSO 4 ). Removing the solvent afforded 287 mg of a yellow oil consisting of approximately 40% 9 and 35% 11, together with about 15% of 1 formed by double methylation and 10% residual 15. The use of more than 0.6 eq. dimethyl sulfate was unfavorable, although the starting material would be consumed completely, but methylation of already formed 9 and 11 to yield 1 became the dominant reaction. Route B: Under an argon atmosphere, magnesium turnings (450 mg; 18.5 mmol; according to Grignard, Sigma Aldrich, Steinheim, Germany) were added to 50 ml dry THF. Methyliodide (2.7 g, 19 mmol, 1.2 ml) was added over a time period of 20 min so that the temperature not exceeded 30°C. The suspension was stirred for another 2 h and 1 (2.88 g, 16.2 mmol, dissolved in 5 ml THF) was added dropwise. The reaction mixture was refluxed 2 h and additional 10 h at room temperature. Then, the suspension was poured on ice. The aqueous phase was extracted two times with 100 ml ethyl acetate. The combined organic phases were dried (MgSO 4 ) and the solvent was removed in vacuo to yield 2.46 g of an dark orange oil consisting of approximately 50% 9 and 40% 11, together with 5% residual 1.
Analysis of 9: R f = 0.63 (EtOAc/Hexan 1:4); 3,4-Dihydroxyeugenol (15) was prepared by the method proposed by Kraft and Eichenberger (2003) 3370, 3078, 2978, 2903, 2835, 1638, 1605, 1524, 1444, 1354, 1281, 1258, 1194, 1147, 1113, 995, 964, 914, 863, 813, 788, 758, 650, 591, 455 , and 419 cm −1 .
RESuLTS
Human, bovine, and rat (Aroclor 1254-induced and non-induced) liver microsomes were incubated with 1 in the presence of an NADPH-generating system to encompass metabolites formed by metabolic phase I reactions. After workup, incubation supernatants were analyzed by RP-HPLC/ DAD. Peaks of metabolites were separated and examined using LC/MS and 1 H-NMR spectroscopy. Concentrations of the main metabolites and decrease in substrate concentration were monitored in microsomal incubations from different species (human, rat, and bovine) at various concentrations using quantitative HPLC/DAD analyses. Cytotoxicity of the metabolites using the RRA as well as the LLA was measured in pRHs in culture. Levels of phase I metabolites and phase II conjugates were monitored in pRH. The formation of DNA-adducts with dA and dG after incubation of pRH with the metabolites at noncytotoxic concentrations was determined.
Oxidative Metabolism of 1 in Liver Microsomes
By far the widest spectrum and the highest yield of metabolites were detected in incubations with ARLM. The time course of the levels of metabolites generated during incubations of ARLM with 500 µM of 1, as well as the decrease of 1 are displayed in Figure 1 . Equal concentrations of internal standard 14 were added after the incubations. As early as 2 h after starting the incubation, the level of 1 had decreased by about 90%, the residual concentration remaining almost constant afterwards.
In addition to nonmetabolized 1 and internal standard (14, added for quantifications), 10 metabolite-derived peaks were detected eluting between 6 and 26 min. Large-scale incubations up to an incubation volume of 100 ml and a substrate concentration of 2.0 mM were performed to yield amounts of metabolites sufficient for identification by 1 H-NMR spectroscopy. According to the conditions used for analytical HPLC analyses, major peaks were separated by preparative HPLC. The largest two peaks, eluting at t R = 16.4-16.8 min, were found to result from a mixture of the side-chain-hydroxylated metabolites 2 and 3. The LC-MS/MS data and the comparison of the 1 H-NMR-spectra of the isolated peaks (t R between 16.0 and 17.0 min) and synthesized reference compounds confirmed their identity (Supplementary fig. 2 ). The peak eluting at 24 CARTUS ET AL. 20.3 min was identified as the ring-hydroxylated metabolite 4. Comparison of the 1 H-NMR-spectra of the separated peak with synthesized 4 together with the LC-MS/MS data approved the identity (Supplementary fig. 3 ). The metabolite forming a peak at 11.0 min was identified as the dihydrodiol 7 by comparing the 1 H-NMR-spectra of the separated metabolite with synthesized 7 (Supplementary fig. 4 ). The masses and transitions (LC-MS/MS) confirmed the identity of 7. The relatively broad peak displaying a maximum at t R = 24.3 min and a shoulder at 24.7 min was produced by the demethylation products 9 (t R = 24.3 min) and 11 (t R = 24.7 min). We synthesized 11 by two different methods and succeeded in separation from its isomeric by-product 9 using preparative HPLC. Both compounds have expectedly quite similar NMR-spectra, but a distinction is possible by the different chemical shifts of the signals of the OH and the H1´ protons (Supplementary fig. 6 ). The identity of both compounds is supported by their LC-MS/MS data, although they did not generate characteristic, i.e., the same product ions. Both compounds were found to have the same UV spectra and molar extinction coefficients as well. However, we failed in isolating a sufficient amount in order to measure NMR spectra of 9 or 11 formed in microsomal incubations. Therefore, identification was merely achieved with respect to the retention times, mass signals, and UV/vis spectra of the metabolites compared with commercial 9 and the synthesized 11. The identical UV/vis-spectroscopic properties allowed the quantification of the sum of 9 and 11. Modifying the otherwise used HPLC gradient to enforce almost baseline separation of 9 and 11 allowed the determination of the 11:9 ratio (Table 1 ; Supplementary fig. 6G ). The twice demethylated compound 15 was not detected in any incubation.
The side-chain aldehyde 6 became observable 1 h after starting the incubation as a "negative" peak at t R = 18.7 min. This was due to the reference wavelength of 340 nm used in Figure 1 at which 6 exclusively shows a strong absorption together with a marked relative minimum (270 nm) near the detection wavelength of 280 nm. The identity of 6 was 5 ) and LC-MS/MS. Quantification of this metabolite was achieved at a detection wavelength of 340 nm and a reference wavelength of 450 nm. The corresponding ketone 5 (t R = 19.3 min) was detectable already 1 h after adding the NADPH-generating system to the incubation mixture. At a retention time of 6.3 min, acid 13 appeared already 20 min after starting the incubation and reached a concentration maximum after 3 h. A small amount of 12 (t R = 21.3 min), an isomerization product of 4, which is also formed by incubation of synthetic 4 with ARLM (Supplementary fig. 10 ), could also be detected. It should be noted that the quantities of these minor metabolites, i.e., 5, 12 and 13, were too low (even in large-scale incubations) neither to apply them to NMR spectroscopy nor to generate sufficient intensities of characteristic product ions at the LC-MS/MS. Thus, their identification is based on the evidence of identical retention times, characteristic UV spectra, and the fact, that they were detected unequivocally as secondary metabolites by the incubation of 2, 4, and 3, respectively (Table 2) .
Another metabolite forming a minor peak with a retention time of 13.4 min (u1) could not be identified. The concentration of this metabolite was found to increase over the first 3 h. After 21 h, however, u1 was no longer detectable. The major metabolites 2, 3, 4, 9, and 11 became rapidly detectable almost reaching steady state after 3 h, whereas 5, 6, and 12 were first detectable 60 min after starting the incubation. The diol (7) was detectable from start of the incubation and increased constantly over the observed time period, whereas the probable precursor 8 was not found in any incubation.
Incubations of 1 with liver microsomes from humans, untreated rats, and of bovine origin resulted in a lower number and amount of metabolites. The time course of HPLC elution patterns is shown in Supplementary fig. 7 . Quantification of the time-course of metabolite levels in incubations (500 µM) using liver microsomes from different species is depicted in Figure  2 . The substrate 1 and the metabolites 2-4, 6, and the sum of 9 + 11, could be quantified. For clarity, the concentrations of the minor metabolites 6 and 9 + 11 are given as sum. The concentrations of the metabolites 5 and 13 were below the limit of quantification in all incubations. Quantifiable amounts of 12 were found only in incubations of HLM and BLM.
Differences in the concentrations of metabolites, expressed as percentage of the starting substrate concentration betweeen the three investigated species (rat, bovine, and human), at two different substrate concentrations (100 and 500 µM) are shown in Table 1 . Hydroxylations in 1´ and 3´-position were dominating in all microsomal incubations. Although 2 and 3 were found to be present at nearly equal concentrations in incubations with RLM and HLM at both substrate concentrations, the level of 2 prevailed in incubations with ARLM (500 µM) and BLM (100 and 500 µM). 4 was a major metabolite found in incubations with ARLM (500 µM) and at lower concentrations also in BLM. However, it was not detected in incubations with RLM and could not be quantified in incubations with HLM, both after 2 h. After 21 h, however, minor amounts of 4 and 12 were found in HLM.
Incubation of ARLM With Synthesized Metabolites
In order to elucidate the metabolic pathways and for a more precise specification of minor metabolites generated during incubations with 1, ARLM were incubated with synthesized compounds 2, 3, 4, 8, and 9. After work-up, the supernatants of these incubations were applied to HPLC analysis. Table 2 summarizes the detected secondary metabolites.
Incubation with 2. In incubations of 2, about 73% of the substrate was recovered nonmetabolized after 3 h. Two metabolites could be detected with retention times of 9.0 and 20.0 min, respectively (Supplementary fig. 8 ). The metabolite eluting at t R = 20.0 min was identified as the ketone 5. The retention time of the other yet unknown metabolite (t R = 9.0 min) is indicative for an alkenyl benzene carrying two hydroxy groups, e.g., 1´,6-dihydroxymethyleugenol or 1´-hydroxyeugenol. 3 could not be found in these incubations, suggesting that 3 is not an isomerization product of 2, but is formed directly from 1.
Incubation with 3.
In incubations of pure metabolite 3, five secondary metabolites were detected besides nonmetabolized substrate (57%) after 3 h (Supplementary fig. 9 ). As previously reported in a study on methylisoeugenol (Cartus et al., 2011) , three of these could be identified. The peak at t R = 18.7 min was identified as the aldehyde 6. According to their retention times and spectral properties, the compounds eluting at t R = 10.5 and 6.3 min are presumed to be a dihydroxy compound and 13, respectively. In contrast, the compounds with t R = 11.7 and 12.3 min displayed strong absorbance at 261 nm and weaker absorbance at 280 nm, characteristic for compounds carrying a 2-propenyl side chain. The retention times point to dihydroxy derivatives of 1 (e.g., bearing one hydroxyl group at the side chain and another at the aromatic ring). However, preparative separation of these secondary metabolites failed, so identification via NMR spectra was not feasible.
Incubation with 4.
After 3 h incubation of ARLM with 4 (t R = 20.0 min, Supplementary fig. 10 ), 71% were found as nonmetabolized and about 6% were isomerized leading to 12 (t R = 21.4 min). In addition, three further metabolites (t R = 19.0; 12.9 and 12.3 min) could be detected. A peak with the same retention time (12.3 min) and UV-spectrum as from incubations with 3 (see Incubation with 3) was found, suggesting that this secondary metabolite is 3´,6-dihydroxymethylisoeugenol. Based on their UV-spectra, it was concluded that the metabolite with t R = 19.0 min bears a 2-propenyl side chain and the metabolite with t R = 12.9 min is assumed to carry an allyl or saturated side chain.
Incubation with 8. The side-chain epoxide 8 had completely disappeared in ARLM already after 12 min at a starting concentration of 500 µM (Supplementary fig. 11, top) . A similar picture was obtained at other starting concentrations of 8 ranging from 50 to 1000 µM (data not shown). The re-26 CARTUS ET AL.
FIG. 2. Quantification of metabolite levels during incubation of liver microsomes with 1. (A) ARLM (rat, Aroclor-induced); (B) RLM (rat non-induced); (C) BLM (bovine); (D) HLM (human)
. Initial concentration of 1 was 500 µM; concentration of 14 (internal standard) was 500 µM. Values are means ± SD from three independent incubations × sum of metabolites; ■ 1; ▲ 2; △ 3; 4; ◀ 6, 7, 9, 11; 12. Methyleugenol (1) 18.1 ± 0.2 71.5 ± 4.5 51.2 ± 5.2 285.5 ± 24.6 22.9 ± 2.1 259.5 ± 24.7 10.9 ± 3.0 257.5 ± 13.4 1´-Hydroxymethyleugenol (2) 39.4 ± 2.9 203.5 ± 14.4 9.2 ± 0.4 52.0 ± 2.1 29.8 ± 1.2 85.0 ± 5.6 21.9 ± 1.2 64.5 ± 5.4 3´-Hydroxymethylisoeugenol (3) 9.8 ± 3.0 38.5 ± 0.5 10.4 ± 2.8 48.5 ± 1.3 12.4 ± 0.9 32.0 ± 0.4 21.8 ± 1.0 64.0 ± 1.0 6-Hydroxymethyleugenol (4) 7.6 ± 3.9 61.0 ± 0.4 ND NQ 17.7 ± 0.2 19.5 ± 0.04 ND 3.0 ± 0.00 3´-Oxomethylisoeugenol (6) ND 10.5 ± 0.1 0.6 ± 0.2 6.0 ± 0.02 0.5 ± 0.1 6.5 ± 0.01 1.1 ± 0.1 11.5 ± 0.02 (RS)-2´,3´-dihydroxy-2´, 3´-dihydromethyleugenol (7) ND 3.5 ± 0.0 1.6 ± 1.4 6.5 ± 0.02 3.8 ± 0.9 7.0 ± 0.01 8.9 ± 1.7 10.5 ± 0.02
Eugenol (9 METABOLISM OF METHYLEUGENOL action product was identified as diol 7 (t R = 11.0 min). The formation of a shoulder (t R approx. 10.0 min) was found to depend on the pH value. Depending on the starting concentration of 8, 81-98% could be recovered as diol 7 after 10 min of incubation. The reaction was independent of the cofactor NADPH. Because diol 7 was not detectable in control experiments, e.g., with heat-inactivated microsomes, even after 30 min of incubation (Supplementary fig. 11 , bottom), the reaction needs active protein, probably microsomal epoxide hydrolase (mEH). A 3-h incubation of ARLM with synthesized 7 (500 µM) produced no detectable new metabolites, but 92% of the substrate were found to be nonmetabolized (data not shown). Thus, the diol 7 is obviously a final product of the oxidative metabolism of 1. Incubation with 9. In general, 9 was poorly metabolized. Incubation of ARLM with 9 revealed three peaks in the chromatogram. 10 (t R = 25.5 min) was identified to be a secondary metabolite of 9. The identification of the two other metabolites (t R = 11.5 and 11.9 min) failed due to the low amounts present in the incubation supernatants. The UV-spectra of the compound at 11.5 min had a maximum at 280 nm and the other at 262 nm. Together with their retention times, a plausible assumption would be that these metabolites are 1´-hydroxyeugenol and 3´-hydroxyisoeugenol. We tested 9 in all four types of microsomes and could detect these three secondary metabolites in any of these. However, the recovery of nonmetabolized 9 was still high in all incubations ranging from 67% (RLM) to 81% (HLM). ARLM and BLM incubations showed the highest yield of 10, whereas relatively high amounts of the metabolites at 11.5 and 11.9 min were found in ARLM and RLM (Supplementary fig. 12 ).
Based on these results, the metabolic pathways of 1 in liver microsomes are summarized in Figure 3 .
Cytotoxicity
To investigate the contributions of the identified metabolites to the hepatotoxicity of 1 and to determine appropriate incubation concentrations for further experiments (DNA adducts), 28 cytotoxicity was determined via RRA and LLA in incubations of pRHs in culture with the synthetic metabolites 2-6 and 8 for 24 h each. The EC 50 values determined by the RRA as well as the LLA are shown in Table 3 . The parent compound (1) was found to have an EC 50 value of 307 ± 52 µM in the RRA. Higher cytotoxicity was found for ketone 5 and the suggested proximate carcinogen 2. The other investigated metabolites showed slightly lower (4, 6, and 8) or clearly lower (3) hepato-cytotoxicity compared with 1. In the LLA, EC 50 values were generally higher than in the RRA with the exception of 3.
Metabolism of 1 in pRHs
In Figure 4 , the time course of metabolite levels in incubations of Aroclor 1254 pretreated pRH with 1 (250 µM) is shown. Figure 4A illustrates chromatograms where the supernatants were applied directly to HPLC analysis, whereas Figure 4B shows separation results after additional postincubation with β-glucuronidase/sulfatase. The concentration of substrate 1 decreased continously over the observed time period and it was no longer detectable after 24 h (data not shown). Major metabolites of 1 in pRH were, similar to microsomal incubations with ARLM, the alcohol 2, which was mainly nonconjugated, and the phenol 4, which was nearly completely conjugated (as glucuronide or sulfate). Minor metabolites were the diol 7 (partially conjugated) and the demethylated metabolites 9 and 11, which were not detectable prior the incubation with β-glucuronidase/sulfatase. The concentrations of all detected metabolites increased steadily over 5 h of incubation. In contrast to the microsomal incubations, neither 3, nor the oxo compounds 5 and 6 were found. However, two yet unknown metabolites (t R 7.5 and 9.4 min) were detectable. The concentrations of metabolites identified in pRH incubations are summarized in Table 4 .
It should be noted that incubation of pRH with 1 without pretreatment with Aroclor 1254 revealed only very low metabolite concentrations, which were not quantifiable although the starting concentration of 1 decreased down to about 73% after 5 h of incubation (data not shown). This may be partly due to rapid formation of 2, its sulfation, and subsequent binding to cellular target molecules.
DNA Adduct Formation in pRH
We determined the formation of DNA-adducts by incubation of pRH with 1 and the synthesized metabolites 2-6, 8, and methylisoeugenol at the highest noncytotoxic concentrations over 2 and 12 h, respectively. Quantification was optimized to detect any adducts with dG and dA linked at the 3´-end of the side chain of the test compounds (Herrmann et al., 2012) . 1 and several metabolites (2, 3, 6) formed N 2 -MIE-dG in rat hepatocytes in primary culture (Table 5 ; UPLC-MS/MS-traces of adducts and internal standard are shown in Supplementary fig. 1 ). Samples showing high levels of these adducts also contained the corresponding dA adduct, N 6 -MIE-dA. However, levels of dA adducts were approximately 50 times lower than those of the dG adduct. Similar ratios of both adducts were previously detected in S. typhimurium strain TA100-hSULT1A1*1Y, expressing human SULT1A1, after treatment with 2 or 3 (Herrmann et al., 2012) . Extension of treatment with 1 from 2 to 12 h led to a nearly 10-fold increase in the level of adducts detected. Although 2 was used at only one-tenth of the concentration of 1, it formed substantially higher levels of adducts. Moreover, high levels were already observed after 2 h, indicating that the activation (probably via sulfation) was relatively fast. 3 was much less efficient in forming DNA adducts than its isomer 2. Moreover, adducts were only detected with 3 after the short treatment period (2 h) but not after 12 h. 6, used at higher concentration than 3, showed formation of modest levels of adducts at both time points. The other compounds tested (methylisoeugenol, 4, 5, and 8) did not produce detectable levels of N 6 -MIE-dA or N 2 -MIE-dG adducts under the used analytical conditions.
DISCuSSION
Previous investigations on the metabolism of 1 and its metabolites were designed to clarify the kinetics in a physiologically based kinetic model (using different tissue fractions, Al-Subeihi et al., 2011) or to determine the role of various human CYPs in the formation of 2 (Gardner et al., 1997; Jeurissen et al., 2006) , the precursor of the mutagenic sulfate conjugate 2. A major result of these studies was the finding of a large variability in the capacity to generate 2 among liver microsomes from different human individuals (Gardner et al., 1997) . Instead, this study aimed at elucidating which phase I metabolites, including virtually all (major and minor) metabolites, can be found in liver microsomes from different species and which pathways connect those metabolites. Therefore, our experiments required a minimum substrate concentration allowing detection, identification, and quantification of metabolites. As a result, we provide a virtually complete spectrum of phase I metabolites detected in liver microsomes from untreated rats (RLM), ARLM, BLM, and pooled HLMs.
Our findings are in good concordance with the report by Solheim and Scheline (1976) , who determined metabolites of 1 in urine and bile of rats having received a single dose 254.1 ± 7.0 164.2 ± 8.1 105.7 ± 5.8 123.3 ± 9.8 71.2 ± 1.4 83.6 ± 13.6 54.1 ± 4.3 52.4 ± 7.9 35.1 ± 1.8 31.6 ± 2.4 24.6 ± 0.7 1'-Hydroxymethyleugenol (2) ND 26.9 ± 2.6 35.3 ± 3.0 44.4 ± 4.9 51.1 ± 1.6 52.4 ± 3.2 63.6 ± 4.1 52.9 ± 2.0 63.1 ± 3.6 46.5 ± 2.2 57.0 ± 3.7 Eugenol + chavibetol (9 + 11) ND ND NQ ND NQ ND 2.4 ± 0.6 ND 2.6 ± 0.6 ND 2.6 ± 1.4 (RS)-2´,3´-Dihydroxy-2´, 3´-dihydromethyleugenol (7) ND ND NQ NQ NQ 2.2 ± 0.3 5.0 ± 0.5 3.6 ± 0.5 8.6 ± 0.8 4.6 ± 1.1 11.5 ± 0.5 6-Hydroxymethyleugenol (4) ND 11.0 ± 1.4 23.8 ± 2.9 6.6 ± 0.6 34.8 ± 1. (2011) in rat liver microsomes. In contrast to the latter study, we were unable to detect epoxide 8 in any incubation. In fact, 2´,3´-allylic epoxides of allylbenzenes, e.g., from estragole, safrole, or 9, have been reported to serve as good substrates for mEH (Luo et al., 1992) . Epoxides are supposed to be metabolized by EH in a two-step mechanism including the rapid formation of a substrate-ester intermediate and the (slower) hydrolysis of the ester (Oesch et al., 2004) . Continuously generated epoxide 8, formed in minor concentrations would be rapidly absorbed by mEH, thus escaping detection, hydrolyzed, and released as diol 7. Covalent binding of eugenol-2´,3´-epoxide to DNA in vitro has been reported, but addition of mEH abrogated the formation of DNA adducts (Luo and Guenthner, 1996) . However, we found in all incubations only minor amounts of the corresponding diol 7, which was, in the case of pRH incubations, partly conjugated. Other "reactive metabolites," i.e., metabolites 5 and 6 (which may be capable of forming Michael adducts), were detected during microsomal but not during pRH incubations. These "reactive metabolites" 5 and 6, also including 8, may react, e.g., with amino acids and proteins, thus possibly playing a role in liver toxicity and hapten formation. In fact, Gardner et al. (1996) found protein adducts in the livers of rats treated with 1. The authors suggested that the 1´-hydroxylation step plays a major role in adduct formation, whereas our findings indicate that other metabolites may be protein-reactive as well. The low concentration of the "reactive metabolites" in microsomal incubations and their absence in pRH opens two possibilities: (1) they are simply not formed, or just in small amounts during incubations; (2) they may rapidly generate adducts with microsomal proteins and other cellular constituents. The latter option is supported by the fact that aldehyde 6 and epoxide 8 were found to induce DNA strand breaks (after 24 h) in a concentration-dependent manner (10-100 µM) in the comet assay using V79 cells (Groh et al., 2012) . In pRH in culture, we were unable to detect dG or dA DNA adducts after incubation of 8, whereas adducts were formed with 6. In agreement with this finding, 6 was able to induce DNA strand breaks in V79 cells after 24 h of incubation at 100 µM (Groh et al., 2012) .
The levels of 2 and 3, i.e., hydroxylation products of the side chain of 1, were predominating in all types of microsomes investigated, whereas 3 was found not to be an isomerization product of 2 as shown in incubations of synthetic 2 with microsomes. The amount of 2 detected was correlated with the total CYP content of the microsomes, i.e., ARLM > BLM > HLM > RLM. In contrast, levels of 3 were low in ARLM and BLM, but they were found to be in the same range as 2 in HLM and RLM. Surprisingly, 3 was not detected in pRH incubations, neither nonconjugated nor after postincubation with glucuronidase/ sulfatase. Accordingly, incubations with synthetic 3 in ARLM have revealed a relatively pronounced further metabolism of 3 leading, among others, to the reactive 3´-oxo metabolite 6. Thus, further enzymatic and nonenzymatic steps may cause "disappearance" of 3 in intact cells.
The ring-hydroxylated metabolite 4 could be quantified in incubations of ARLM and BLM. In HLM, 4 could only be detected in small amounts and only after a prolonged incubation period of 21 h indicating a pronounced difference between induced rat, bovine, and human metabolism of 1. In noninduced RLM, also 4 just exceeded the limit of detection. Minor levels 6-Hydroxymethyleugenol might form adducts that differ from N 6 -MIE-dA and N 2 -MIE-dG by the presence of an additional oxygen atom. Therefore, the corresponding DNA digests were additionally analyzed for products with m/z transitions of 444 → 328 (dA adducts) and 460 → 344 (dG adducts). The result was negative.
c Reaction of the oxirane ring with nucleophilic structures of the DNA might lead to adducts that differ from N 6 -MIE-dA and N 2 -MIE-dG by the presence of an additional oxygen atom and two hydrogen atoms. Therefore, the corresponding DNA digests were additionally analyzed for products with m/z transitions of 446 → 330 (dA adducts) and 462 → 346 (dG adducts). The result was negative.
METABOLISM OF METHYLEUGENOL (< 0.5%) of 12, the isomer of 4, were observed in ARLM, BLM, and HLM from incubations of 1. Although ARLM were found to be highest in the levels of 4, the concentrations of 12 were even higher than that of 4 in incubations with BLM and HLM. Incubations of ARLM with synthetic 4 revealed 12 as the main metabolite suggesting an enzymatic isomerization. We also found a reaction leading into the opposite direction, i.e., from a propenylic to an allylic side chain, in incubations with synthetic 12 (Cartus et al., 2011) indicating an isomerization equilibrium between 4 or 12 upon these steps.
The demethylated products 9 + 11 were detected as minor metabolites in microsomal and, conjugated to glucuronic acid or as sulfate, in pRH incubations. 9 may represent a "reactive metabolite" as well because 9 was found to generate electrophilic quinone methide intermediates (Thompson et al., 1991 (Thompson et al., , 1995 , which can react with cellular macromolecules. 15, the twice demethylated compound, could not be detected in any incubation, possibly due to the same reasons (formation of an ortho-quinone or para-quinone methide). Because of the meta-substitution of the OH group, 11 cannot form a quinone methide directly.
The cytotoxicity findings confirm the outstanding potency of the 1´-derivatives (2 and 5) to cause cell damage. All other metabolites investigated showed EC 50 values in the range of 1 or above. In particular, 3 had a remarkably low cytotoxicity (EC 50 above 1 mM) in both the RRA and the LLA, and 6 as well as 8 were very weak toxicants in the LLA.
Also in terms of DNA adduct formation, 2 was the most potent among all metabolites tested underlining the outstanding role of 2 as a proximate mutagen/carcinogen formed from 1. In comparison, 3 only formed adducts to dG after 2 h of incubation at a much higher, although noncytotoxic, concentration of 200 µM.
The parent compound (1) formed DNA adducts to dA and dG to a smaller extent than 2 after 12 h. Aldehyde 6 formed little dG adducts after 2 and 12 h. It has to be considered, however, that the relatively reactive 6 was added to the hepatocyte cultures requiring uptake and distribution into the cells, a situation clearly different from intracellular formation of the metabolite. We also took into consideration the possibility that 4 and 8 may form adducts different from N 6 -MIE-dA or N 2 -MIE-dG. However, an extensive search for plausible candidate adducts gave negative results (footnotes b and c to Table 5 ). As no standards for these adducts were available, the limits of detection are unknown.
In summary, our findings demonstrate that microsomes from human, rat, and bovine liver are capable of forming a broad spectrum of phase I metabolites from the genotoxic compound 1, which is abundant in natural food, as well as being a constituent of flavoring preparations in foods, beverages, and cosmetics. 1´-Hydroxylation, considered to form the proximate genotoxic and carcinogenic metabolite 2, was the major pathway of 1 in microsomes from all species tested. The second major metabolic step of 1 in bovine and ARLM, ring hydroxylation at position 6 leading to 4, was not or hardly detectable in microsomes from humans and RLM. HLMs also differed markedly from the other microsomal preparations in other respects because they showed considerable amounts of the side-chain dihydrodiol 7 and metabolite 3, the 3´-hydroxylated product. The latter was shown to be the precursor of the potentially reactive carbonyl intermediate 6, whereas the dihydrodiol is derived from the epoxide 8. Both, the epoxide and the 3´-aldehyde have the capacity to bind to proteins and other hepatic macromolecules being probably involved in liver toxicity and hapten formation. DNA adduct formation confirmed the outstanding role of 1´-hydroxylation in the genotoxicity of 1. However, both 6 and its possible precursor 3 were also able to form DNA adducts, suggesting that metabolic pathways other than 1´-hydroxylation may also contribute to the carcinogenicity of 1. Cytotoxic metabolites possibly also involved in hapten formation were the 1´-derivatives 2 and 5 (alcohol and aldehyde), whereas the others including the 2´,3´-epoxide 8 are obviously detoxified more efficiently, at least when added to hepatocyte cultures.
In conclusion, our findings provide evidence for additional metabolic pathways leading to potentially reactive intermediates besides the well-described 1´-side-chain hydroxylation. These pathways should be considered in future risk assessment of 1 with a special focus on covalent modification of cellular target molecules.
The species comparison of the microsomal metabolite patterns did not reveal any fundamental differences in the amounts of reactive metabolites formed from 1. For reasons of metabolite detection and identification, the substrate concentrations used in our experiments were much higher than those probably present in human tissues after (dietary) 1 exposure. A future challenge will be to bridge the gap between these concentration ranges to obtain more reliable risk estimates of human exposure.
Future studies will also be aimed at investigating in more detail the aspects of hapten-derived sensitization via metabolism of 1, and the kinetics of formation and turnover of all metabolites at lower substrate concentrations, particularly in human experimental models.
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